Evidence map›Paper›PMID 28881668›Full record

ArticleOncotarget2017

The metastasis suppressor CD82/KAI1 regulates cell migration and invasion via inhibiting TGF-β 1/Smad signaling in renal cell carcinoma.

Jundong Zhu, Chao Liang, Yibo Hua, Chenkui Miao, Jianzhong Zhang, Aiming Xu, Kai Zhao, Shouyong Liu, Ye Tian, Huiyu Dong and 5 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Jundong Zhu *Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Chao Liang *Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yibo Hua *Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Chenkui MiaoDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jianzhong ZhangDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Aiming XuDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Kai ZhaoDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Shouyong LiuDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Ye TianDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Huiyu DongDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Chao ZhangDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Pu LiDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Shifeng SuDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Chao QinDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Zengjun WangDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Nanjing Medical University · CNJiangsu Province Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tetraspanin KAI1/CD82 was identified as a tumor metastasis suppressor that downregulated in various malignant cell types. However, the function of CD82 and its underlying anti-metastasis role in renal cell carcinoma (RCC) is still unraveled. Here, we investigated the expression of CD82 in RCC and explored its regulatory mechanism in RCC cell lines. We found that CD82 was down-regulated in RCC tissues and cells and its expression was significantly associated with histological grade(p=0.041), tumour stage (p=0.036) and tumor size(p=0.020) by analyzing tissue microarrays. After upregulation of CD82 through lentivirus, reduced ability of migration and invasion in Caki-1 cells were detected. In contrast, gene silencing of CD82 by small interfering RNA promoted metastatic and invasive potential of 786-O cells. Furthermore, Western blot was performed to identify the influence of CD82 on MMP family and TGF-β1/Smad pathway in RCC. Subsequently, upregulating protein level of TGF-β1 with the overexpression of CD82 could rescue the malignant behaviors inhibited by CD82 which indicated that CD82 played its inhibitory role in RCC partially by attenuating the expression of TGF-β1. Taken together, CD82 played a prominent role in migration and invasion of RCC cells and it might exhibit its inhibitory role in RCC metastasis via block TGF-β1/Smad signaling pathway.

Indexed as

CD82/KAI1migration/invasionrenal cell carcinomatetraspaninTGF-β1/Smad signaling

Identifiers

PMID28881668
PMCPMC5584269
OpenAlexW2619445516

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.